1[1]Wells RJ, Odom LF, Gold SH, et al. Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia:initial response and relationship to multidrug resitance gene 1[J]. Med Pediatr Oncol, 1994, 22(4):244-249.
2[2]Koc Y, Akpek G, Kansu E, et al. Bolus and continuous infusion mitoxantrone in newly diagnosed adult acute lymphoblastic leukemia:results of two consecutive phase Ⅱ clinical studies[J]. Cancer Invest,1998, 16(6):355-365.
3[1]Bellosillo B, Colomer D, Pons G, et al. Mitoxantrone, a topoisomerase Ⅱ in hibitor, induces apoptosis of B-chronic lymphocytic leukemia cells. Br J Haematol, 1998, 100(1):142
4[2]Kravtsov VD, Greer JP, Whitlock JA, et al. Use of the mieroeulture kinetic assay of apoptosis to determine chemosensitivities of leukemias. Blood, 1998, 92(3):968
5[3]Thomas X, Archirnbaud E. Mitoxantrone in the treatment of acute myelogenous leukemia: a review. Hematol Cell Therapy,1997. 39:163
6[4]Bezwoda WR, Bernasconi C, Hutchinson RM, et al. Mitoxantrone for reffactory and relapsed acute leukemia. Cancer,1990, 66:418
7[5]Solary E. Wiry B, Caillot D. et al. Combination of quienie as a potential reversing agent with mitoxantrone and cytoarabine for the treatment of acute leukemia: a randomized multicenter study. Blood. 1996, 88:1198
